Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

With Obesity Drug Demand Surging, Is Novo Nordisk a Buy?

Novo Nordisk (NVO) continues strengthening its obesity portfolio and marking new milestones. The company’s solid product demand, strategic investments, and developments are the key drivers for its growth and success. So, let’s examine whether NVO is an ideal investment choice. Read more to find out.

StockNews.com · Sep 12, 2024

Weight-loss drug Saxenda effective for kids as young as 6, study shows

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with diet and exercise

The Independent UK · Sep 10, 2024

Ozempic maker sued over claims the weight-loss medication led to woman’s colon removal

Doctors had to remove parts of her intestines due to what she claims were side effects from taking weight-loss medication

The Independent UK · Sep 6, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Scientists Confirmed An Important Connection Between Semaglutide and Mental Health

Researchers found that semaglutide, compared with a placebo, didn't significantly increase depressive thoughts.

Inverse · Sep 4, 2024

Denmark gets Novo Nordisk to lower Ozempic prices

As Congress pushes for Medicare to cover anti-obesity drugs, puzzlement remains about who should get them, for how long, and at what price.

Fortune · Aug 7, 2024

Novo Nordisk cuts profit outlook after weaker sales of weight-loss drug Wegovy

Danish company, which also makes Ozempic, faces increasing competition from US rival Eli Lilly

The Guardian - UK · Aug 7, 2024

Weight loss drug Ozempic sales grow nearly 50% in the US, says maker Novo Nordisk

A surge in demand for weight loss drug Ozempic has helped Novo Nordisk post a 25% jump in revenues in the first half of the year, the Danish company said today.

Evening Standard · Aug 7, 2024

Read news from The Economist, FT, and more,
with one subscription

Should You Be Investing in Nordic Companies?

Should you be Investing in Nordic companies? This corner of Europe presents unique opportunities for investors.

Kiplinger · Aug 4, 2024

Weight-loss drug could help slow Alzheimer’s cognitive decline, trial finds

Liraglutide appeared to reduce brain shrinkage in people with early-stage Alzheimer’s, a small UK study reports

The Guardian - UK · Jul 30, 2024

Surging demand, soaring price tags lead to fake Ozempic doses

A rise in counterfeit versions of sought-after weight loss drug has led to a series of hospitalisations.

Al Jazeera · Jul 29, 2024

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

Roche is working on bringing its weight-loss medications to patients "faster than anticipated,” making it yet another contender in the weight-loss drug market.

Fortune · Jul 29, 2024

Weight-loss jab to be used to prevent other health problems

Some 17,600 people took part in the trial and were either prescribed Wegovy or a dummy drug

The Independent UK · Jul 23, 2024

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

The Guardian - US · Jul 22, 2024

Novo Nordisk hits out as Dutch agency advises against insurance cover for Wegovy

Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance

The Independent UK · Jul 17, 2024

Get all your
news in one place.

100's of premium titles.
One news app.

Zenger · Jul 11, 2024

Big Pharma’s Monopoly On Ozempic Threatens Access To Diabetes Drug In Communities Of Color

Small pharmacies find difficulty in prescribing the drug due to Big Pharma restrictions on the industry. ‌

StockNews.com · Jul 10, 2024

Will Novo Nordisk's (NVO) Q2 Earnings Reflect Its Market Potential?

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….

Fortune · Jul 9, 2024

These weight-loss startups tell customers they can stop taking Ozempic or Wegovy and stay thin. Doctors disagree

As nearly $1 billion of venture capital dollars have been injected into weight-loss startups since 2023, companies are making unproven claims to attract customers. It’s a new twist on a story as old as the diet industry.

The Independent UK · Jul 9, 2024

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

Shares in Novo Nordisk were down 1.1% after the study

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times · Jul 8, 2024

Eli Lilly Weight Loss Drug Beats Ozempic In Head-to-head Study

Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

The Independent UK · Jul 4, 2024

Ozempic maker slams Biden after the president accused the drug company of ‘ripping off’ US consumers

Remarks came after the president and Senator Bernie Sanders blasted the pharmaceutical giant for its ‘unconscionably high prices’

The Guardian - UK · Jul 3, 2024

Weight-loss jabs may be linked to condition that can cause blindness, study finds

People with diabetes on semaglutide, found in Wegovy and Ozempic, four times more likely to be diagnosed with disease of optic nerve

Evening Standard · Jul 3, 2024

Ozempic weight loss drug linked to higher risk of eye condition that causes blindness

US study says patients could have higher risk of developing NAION

International Business Times · Jul 2, 2024

Biden Calls For Lower Prices Of Ozempic, Similar Drugs

US President Joe Biden on Tuesday called on pharmaceutical giants Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs such as Ozempic, saying firms must stop "ripping off the American people."

Barchart · Jun 27, 2024

1 Huge New Reason This Diet Drug Stock is a Must-Own

The recent announcement that China approved Novo Nordisk's Wegovy is huge. Here's why: In a national survey conducted during 2015-2019 by China’s National Health Commission, more than half of the adult population was either overweight or obese. That's a massive market that just opened up for NVO.

Fortune · Jun 26, 2024

Novo Nordisk’s Wegovy may just have two years to take over China’s market for weight loss drugs

Novo Nordisk's China patent on Wegovy's active ingredient expires in 2026, much earlier than its patents in the U.S., Japan and Europe.

1 … 20 21 22 23

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Imperial College London

Congressional Budget Office

Medical Pharmaceuticals

125 stories

93 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.